Roman Skoracki was named medical director of the Stefanie Spielman Comprehensive Breast Center (SSCBC) at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
Sharon Wilks joined NEXT Oncology’s phase I clinical investigation team, bringing more than 30 years of research and clinical experience to the practice.
A study led by Susan G. Komen Brinker Award winner Carlos Caldas found that there may be a way to predict treatment response in breast cancer patients even before treatment begins. Results will be presented at the 2021 San Antonio Breast Cancer Symposium Dec. 7-10.
The use of multigene sequencing as a therapeutic decision tool improved outcomes for patients with metastatic breast cancer when the genomic alterations identified were ranked in the I/II tiers of the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), according to results from the SAFIR02-BREAST trial.
The investigational oral selective estrogen receptor degrader elacestrant significantly decreased the risk of death or disease progression and increased progression-free survival compared with standard-of-care endocrine therapy for postmenopausal patients with estrogen receptor (ER)-positive/HER2-negative metastatic breast cancers that progressed on prior endocrine and targeted therapies, according to results from the phase III EMERALD trial.
Among patients with hormone receptor-positive breast cancer treated with an aromatase inhibitor plus Ibrance (palbociclib), those who displayed a rising ESR1 mutation detected in their blood before disease progression doubled their median progression-free survival following a switch to Faslodex (fulvestrant) plus Ibrance, according to results from the phase III PADA-1 clinical trial.
Black women experienced higher rates of breast cancer-related lymphedema than white women, and Black race was the strongest predictor of lymphedema development, according to results presented at the San Antonio Breast Cancer Symposium.
The National Coalition for Cancer Survivorship began in 1986 with 23 people at a hotel in Albuquerque and a $100 contribution from Patricia A. Ganz, who recalls thinking: “I don’t think I’ve ever invested in anything that was so good.”
Bridget Oppong was named deputy director of the Center for Cancer Health Equity at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
Helen M. Piwnica-Worms and Fabrice André will be honored for their contributions to breast cancer research by the San Antonio Breast Cancer Symposium and the American Association for Cancer Research, an SABCS cosponsor, at the 2021 SABCS Dec. 7-10.
